FAFN
BCLI

First Affirmative Financial Network’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

First Affirmative Financial Network’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-953
Closed -$4.84K – 287
2024
Q2 		$4.84K Sell
953
-66
-6% -$495 ﹤0.01% 261
2024
Q1 		$8.63K Sell
1,019
-28
-3% -$154 0.01% 251
2023
Q4 		$4.29K Buy
+1,047
New +$3.14K ﹤0.01% 241

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

First Affirmative Financial Network's BCLI Position: Q3 2024 in Review

First Affirmative Financial Network sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 953 shares — an estimated $4.84K sold.

First Affirmative Financial Network first reported a position in BCLI in Q4 2023 and held it in 3 quarters. The position peaked at $8.63K in Q1 2024. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • First Affirmative Financial Network reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • First Affirmative Financial Network sold 953 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $4.84K.
  • First Affirmative Financial Network first reported a position in BRAINSTORM CELL THERAPUTC in Q4 2023 and held it in 3 quarters.
  • First Affirmative Financial Network's BRAINSTORM CELL THERAPUTC position peaked at $8.63K in Q1 2024.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on First Affirmative Financial Network's 13F filing for Q3 2024, filed 10 Oct 2024.